LuciSeta 400 mg Capsule

Description

Discover LuciSeta (Sparsentan), a groundbreaking treatment designed specifically for adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. This innovative medication functions as both an endothelin and angiotensin II receptor antagonist, effectively targeting the underlying causes of proteinuria. With a recommended dosage of 200 mg orally once daily, LuciSeta is clinically proven to reduce protein levels in urine for patients presenting with a urine protein-to-creatinine ratio (UPCR) of 1.5 g/g or higher. Before starting LuciSeta, it’s essential to discontinue any renin-angiotensin-aldosterone system (RAAS) inhibitors, endothelin receptor antagonists (ERAs), or aliskiren to ensure optimal results. Embrace the power of LuciSeta (Sparsentan) and take a significant step towards better kidney health and improved quality of life.